

24 FEB 26 P5 51

SENATE

RECEIVED BY

S. B. No. 2573

(In Substitution of Senate Bill No. 230)

Introduced by Senator Robinhood Padilla

AN ACT
PROVIDING FOR THE MEDICALIZATION OF CANNABIS, EXPANDING
ACCESS TO MEDICAL CANNABIS AS A MEANS OF MEDICAL TREATMENT,
EXPANDING RESEARCH INTO ITS MEDICINAL PROPERTIES,
ENUMERATING PROHIBITED ACTS AND PRESCRIBING PENALTIES
THERE TO

Be it enacted by the Senate and House of Representatives of the Philippines in Congress assembled:

1 **SECTION 1. Short Title.** – This Act shall be known as the "*Cannabis*
2 *Medicalization Act of the Philippines.*"

3 **SEC. 2. Declaration of Policy.** – It is the policy of the State to adopt an
4 integrated and comprehensive approach to health development which shall endeavor
5 to make essential goods, health, and other social services available to all the people
6 at affordable cost. The State shall protect and promote the right to health of the people
7 and instill health consciousness among them. Pursuant thereto, the State shall legalize
8 and regulate the medical use of cannabis which has been confirmed to have beneficial
9 and therapeutic uses for known debilitating medical conditions.

10 **SEC. 3. Definition of Terms.** – *As used in this Act:*

- 11 a. *Cannabis* includes every species and variety of the genus cannabis, whether
12 dried or fresh and flowering or fruiting tops, or any part or portion of the
13 plant and seeds thereof, and all its geographic varieties, whether as a
14 reefer, resin, extract, tincture or in any form whatsoever;
15 b. *Closed Locked and Controlled Facility* refers to a closet, room or other
16 comparable, stationary, and fully enclosed area equipped with secured
17 locks, or other functioning security devices that permit access only to

- 1 authorized personnel of the medical cannabis industry players' cultivation,
2 extraction, processing, manufacturing and production sites and dispensary;
- 3 c. *Debilitating Medical Condition* refers to a condition that is severe,
4 persistent, and seriously affecting the patient's strength and ability to
5 function and carry on most of daily living activities, as identified and
6 included in the Good Clinical Practice to be formulated and developed by
7 the Philippine Medical Cannabis Authority (PMCA) established under this
8 Act;
- 9 d. *Medical Cannabis* refers to cannabis products in their pharmaceutical
10 formulation which shall have detailed and accurate information regarding
11 the concentration of tetrahydrocannabinol (THC) and cannabidiol (CBD) as
12 certified by the Philippine Drug Enforcement Agency (PDEA);
- 13 e. *Medical use* refers to the use of medical cannabis as a complementary
14 treatment to alleviate a qualified patient's debilitating medical condition or
15 symptoms, and shall include its acquisition, possession, transportation,
16 delivery, dispensation, administration, cultivation, or manufacturing,
17 research and development for medical purposes;
- 18 f. *S2 License* refers to a license issued by the PDEA to a Professional
19 Regulatory Commission (PRC)-registered physician; and
- 20 g. *Written Prescription* refers to a document dated and signed by a PRC-
21 registered physician possessing an S2 License, containing the debilitating
22 medical condition of the qualified patient under Section 8 of this Act, the
23 recommended dosage of medical cannabis, and treatment plan for palliative
24 care.

25
26 **SEC. 4. Medicalization of Cannabis.** – The use of cannabis for medical
27 purposes is hereby permitted, as herein provided for in this Act, to treat or alleviate a
28 qualified patient's debilitating medical condition or symptoms. The medicalization of
29 cannabis includes its acquisition, possession, transportation, delivery, dispensing,
30 administration, cultivation, or manufacturing by private individuals or entities only for
31 medical and research purposes.

32 **SEC. 5. Philippine Medical Cannabis Authority.** – There shall be created a
33 Philippine Medical Cannabis Authority, herein referred to as "PMCA" under the
34 Department of Health (DOH), which shall be the principal regulatory agency in the
35 access and use of medical cannabis and in the implementation of this Act. It shall be
36 headed by a Director to be designated by the President of the Republic of the
37 Philippines upon recommendation of the Secretary of Health.

38 The DOH shall organize the Authority, including its staffing pattern, and shall
39 ensure its knowledge, competence, and experience with the use of cannabis and

1 regulation of dangerous drugs for medical purposes. Necessary staffing requirements
2 may be requested from the Department of Budget and Management.

3 The PMCA shall be assisted by an inter-agency Medical Cannabis Advisory
4 Committee.

5 **SEC. 6. Powers and Functions of the Philippine Medical Cannabis**
6 **Authority.** – The PMCA shall have the following powers and functions:

- 7 a. To formulate and adopt a *Comprehensive Cannabis Medicalization Plan*;
8 b. To formulate, adopt and implement *rules, regulations, and guidelines*
9 related to medical cannabis plants, its products and by-products, including
10 but not limited to, propagation, cultivation, planting, harvesting,
11 processing, manufacturing, packaging, labeling, distribution, dispensing,
12 and patient licenses or prescription;
13 c. To establish and maintain an information system especially to track
14 cannabis growth from seed to sale for monitoring and regulation purposes:
15 *Provided*, That the PMCA shall monitor or regulate the cultivation,
16 manufacture, storage, distribution, prescription, dispensation and sale of
17 medical cannabis by licensed dispensaries;
18 d. To formulate, adopt, publish and implement Standard Operating
19 Procedures for every stage of producing medical cannabis, such as, but not
20 limited, to the following:
21 i. Good Clinical Practice (GCP);
22 ii. Good Agriculture Practice (GAP);
23 iii. Good Manufacturing Practice (GMP);
24 iv. Good Distribution Practice (GDP);
25 v. Good Waste Disposal Practice (GWDP); and
26 vi. Good Security Practice (GSP).
27 e. To issue licenses to duly registered entities or persons, private or
28 government, that shall engage as medical cannabis industry players
29 through cultivation, manufacturing, production, dispensing, research and
30 development, and importation and sale of medical cannabis;
31 f. To regularly and continuously conduct research and development on the
32 medical cannabis industry and apply the same to further develop the
33 industry in the country;
34 g. To conduct or sponsor or arrange or permit training and educational
35 programs on specific aspects of the medical cannabis industry: *Provided*,
36 That the said training and educational programs shall be a prerequisite to
37 permitting licensed physicians to prescribe and other medical practitioners
38 to dispense medical cannabis products or by-products;

- 1 h. To establish a Prescription Monitoring System and maintain an electronic
2 database of registered medical cannabis patients, their physicians, and
3 other qualified entities for monitoring and regulation purposes;
- 4 i. To hold seminars, workshops, conferences and information dissemination
5 campaigns on the medical cannabis industry, its products, and by-products,
6 particularly on the therapeutic and medical effects of cannabis as
7 authorized in this Act and the risk associated with the use of cannabis for
8 recreational activities;
- 9 j. To make recommendations to the Commission on Higher Education to
10 include medical cannabis as a subject or course in the curriculum of
11 universities and colleges for academic degrees in agriculture, medicine, and
12 applied science and technology;
- 13 k. To make recommendations to PRC to develop and implement a Continuing
14 Professional Development Program on Medical Cannabis for physicians,
15 pharmacists, and other allied medical and health care professionals;
- 16 l. To hire or contract consultants, local or foreign, individuals or entities, for
17 technical capacity building;
- 18 m. To import for resale in the Philippines for authorized users medical cannabis
19 products from foreign manufacturers or companies: *Provided*, That the said
20 medical cannabis products comply with the safety and quality standards
21 prescribed by PMCA, in consultation with the Advisory Committee as
22 provided for in this Act: *Provided further*, That the testing of any medical
23 cannabis product to determine its potency, consistency, safety and
24 effectivity, as well as compliance with packaging and labeling safety
25 requirements shall remain with the Food and Drug Administration (FDA);
- 26 n. To regulate prices of medical cannabis products in the country;
- 27 o. To accept grants and technical assistance in support of medical cannabis
28 research and development; and
- 29 p. To perform other functions as may be deemed necessary to aid the
30 implementation of this Act.

31 **SEC. 7. Advisory Committee on Medical Use of Cannabis.** – There is
32 hereby constituted an advisory committee on the medical use of cannabis, hereinafter
33 referred to as the Medical Cannabis Advisory Committee (MCAC), which shall assist
34 and provide directions in the formulation, implementation and assessment of the
35 policies, guidelines, and regulations under this Act.

36 The Secretary of Health shall serve as the *ex-officio* chairperson of the MCAC.
37 The Chairman of the Dangerous Drugs Board (DDB), the Directors-General of the FDA
38 and the PDEA, the Secretary of Science and Technology and the Secretary of
39 Agriculture or their respective representatives shall be permanent members of the
40 Medical Cannabis Advisory Committee.

1 The Secretary shall appoint the seven regular members of the MCAC who shall
2 serve for a term of three (3) years. It shall be comprised of three (3) PRC-registered
3 physicians, two (2) experts in the regulation of controlled substances for medical use,
4 and two (2) representatives from nationally recognized organizations of patients with
5 debilitating medical conditions: *Provided*, That the seven regular members must be
6 citizens and residents of the Philippines, of good moral character, of recognized probity
7 and independence, and must distinguish themselves professionally in public, civic or
8 academic service and must have been in the practice of their professions for at least
9 ten (10) years: *Provided, further*, That the regular members shall nominate a Vice-
10 Chairperson from among themselves, and shall receive an honoraria in accordance
11 with existing laws, rules and regulations.

12 The MCAC shall meet once a month or as often as necessary at the discretion
13 of the Chairperson.

14 **SEC. 8. *Qualified Patient.*** – The qualified patient is a person who has been
15 diagnosed by a certifying physician as having a debilitating medical condition as
16 defined in Section 3 (c) and may receive therapeutic or palliative benefits from the
17 use of medical cannabis. Qualified patients shall be registered with the PMCA and
18 assigned a unique alphanumeric identification number and shall be issued a registry
19 card with a quick response (QR) code for verification.

20 If the qualified patient is a minor or is incapable or incapacitated to fully give
21 his consent, regardless of age, the certifying physician shall explain to the patient and
22 to the custodial parent or legal guardian the potential risks and benefits of using
23 medical cannabis. The custodial parent or legal guardian shall signify, in writing, their
24 consent to allow the qualified patient's medical use of cannabis.

25 **SEC. 9. *Issuance of Written Prescription, Requisites.*** – A written
26 prescription allowing the use of medical cannabis shall be recognized and accepted if
27 issued by a physician who:

- 28 a. Is duly licensed by the PRC and in good standing;
- 29 b. Has no previous or existing criminal or administrative case/s; and
- 30 c. Is a holder of an S2 license issued by PDEA and has undergone
31 appropriate medical cannabis training from PMCA.

32 The certifying physician shall not issue a written prescription for his or her own
33 use, or the use of his or her immediate family or relatives within the second civil
34 degree of consanguinity or affinity.

35 The certifying physician shall maintain a record of all his issued written
36 prescriptions. He or she shall be responsible for maintaining a record of every qualified

1 patient prescribed the use of medical cannabis, specifically describing the quantity
2 administered/used, therapeutic/desired effect, and any adverse reaction, at the end
3 of each year.

4 **SEC. 10. *Validity of Prescription.*** – The written prescription issued by all
5 certifying physicians shall include a validity period which shall in no case exceed one
6 (1) year from the date of issuance.

7 **SEC. 11. *Grounds for Revocation of Prescription.*** – Any prescription
8 issued by a certifying physician may be revoked based on the following reasons:

- 9 a. Misuse or diversion of the written prescription;
- 10 b. Failure to abide by the prescribed dosage and form;
- 11 c. The patient no longer suffers from a debilitating medical condition;
- 12 d. The patient has not received a therapeutic or palliative benefit from the use
13 of medical cannabis; and
- 14 e. When the qualified patient has died.

15 **SEC. 12. *Standardized Written Prescription.*** –The PMCA shall develop and
16 require the use of a standardized format for all written prescriptions and the same
17 shall be made available to all certifying physicians.

18 The standardized format shall include the following details: (a) name, date of
19 birth, and address of the qualified patient; (b) a statement that the qualified patient
20 has debilitating medical condition as provided in Section 3 (c) and that the qualified
21 patient is under the certifying physician's care for the debilitating medical condition;
22 (c) recommended form and dosage of medical cannabis; (d) issue and expiry date of
23 the prescription; and (e) name, address, telephone number, handwritten signature.

24 **SEC. 13. *Administration of Medical Cannabis.*** – Medical cannabis may be
25 administered through the following: (a) oral; (b) sublingual; (c) inhalation inhalers;
26 (d) topical; and (e) suppositories.

27 **SEC. 14. *Medical Cannabis Industry Players.*** – Only duly registered
28 entities or persons shall be allowed to engage as medical cannabis industry players to
29 conduct any of the following acts in relation to medical cannabis: (a) cultivation; (b)
30 manufacturing; (c) production; (d) dispensing; (e) research and development; (f)
31 importation; and (g) dispensing and sale: *Provided*, That all industry players shall
32 apply and be issued appropriate licenses by the PMCA and other national government
33 agencies concerned prior to engagement in any business operations as regards
34 medical cannabis: *Provided further*, That industry players shall be strictly regulated
35 and shall, at all times, comply with the provisions of this Act and the rules, regulations,
36 guidelines and standard operating procedures to be formulated for its implementation.

1 **SEC. 15. Cultivation, Production and Manufacturing of Cannabis.** – The
2 specific areas allowable for the cultivation of cannabis shall be identified by the PMCA:
3 *Provided*, That cultivation shall only be permitted in a closed locked and controlled
4 facility and that cultivation shall not be located within one (1) kilometer of the property
5 line of a pre-existing public or private school, college or university, daycare center,
6 child care facility or an area zoned for residential use: *Provided, further*, That colleges
7 or universities conducting research and development on medical cannabis are
8 exempted from the one (1) kilometer radius requirement.

9 The PMCA shall issue appropriate licenses and permits for the cultivation,
10 production, and distribution of medical cannabis subject to DDB guidelines. It shall
11 also adopt measures that will ensure the prevention of misuse and illicit traffic of the
12 cannabis plant, such as the establishment of a cannabis plant monitoring system.

13 The PMCA is hereby authorized to engage consultancy services of foreign
14 cannabis experts for the initial cultivation and production of medical cannabis.

15 The PMCA shall facilitate the initial importation of seeds required for the
16 cultivation and production of medical cannabis: *Provided*, That the imported seeds are
17 used solely for the initial cultivation of locally grown cannabis: *Provided further*, That
18 importation of seeds shall be allowed only in the initial stage of the implementation of
19 this Act or a period of not more than five (5) years or until the industry players are
20 fully capacitated to independently cultivate locally-grown cannabis.

21 **SEC. 16. Medical Cannabis Products.** – Medical cannabis products shall be
22 in the form of edibles, pills, oil, tincture, flower, topicals, and inhalers. Importation of
23 the same products from countries with stringent regulatory agencies or countries with
24 established medical cannabis regimes or countries already using the same medical
25 cannabis products in the last five years, shall be allowed under this Act. Importation
26 of medical cannabis products from countries not using their own products shall be
27 prohibited.

28 **SEC. 17. Medical Cannabis Product Label and Packaging.** – All medical
29 cannabis products shall be properly and adequately labeled like that of any
30 pharmaceutical products. The label shall contain the following information, among
31 others:

- 32 a. CBD and THC content and ratio;
- 33 b. Batch and Series number;
- 34 c. Date of production and expiration;
- 35 d. Clinical Indications and Contraindications;
- 36 e. Dosage and Administration Instruction;
- 37 f. Storage Instruction; and

1 g. Other relevant information as may deemed necessary by the PMCA.

2 **SEC. 18. *Dispensing Medical Cannabis.*** – Prior to dispensing medical
3 cannabis, the authorized dispensaries must require the presentation of the registry ID
4 card, scan the QR code, examine the details, and update the data contained therein
5 after the sale. The QR code shall contain details such as the name of the certifying
6 physician, the assigned unique alphanumeric identification number of the patient, the
7 diagnosed medical condition of the qualified patient, the prescribed dosage, medical
8 cannabis product and formulation, the duration of use, and the complete transaction
9 history of the qualified patient.

10 **SEC. 19. *Authorized Transport Vehicles.*** – Only authorized transport
11 vehicles shall be authorized to carry and transport medical cannabis plants and
12 products.

13 **SEC. 20. *Electronic Verification.*** – The PMCA shall establish a Prescription
14 Monitoring System which shall be made accessible to the PDEA Compliance Service
15 and authorized dispensaries where they may electronically verify and determine the
16 validity of the registry ID card and information on whether the cardholder is a
17 registered qualified patient.

18 **SEC. 21. *Cannabis Plant Monitoring System.*** – The cultivation facilities
19 shall establish and maintain a Cannabis Plant Monitoring System for testing and data
20 collection. It shall be available for inspection of regulatory agencies for purposes of
21 documenting each cannabis plant and for monitoring plant development throughout
22 the life cycle from seed planting to final packaging.

23 **SEC. 22. *Authority of the PMCA to Enter Premises.*** – To ensure
24 compliance with the provisions of this Act, the PMCA may, at all times, enter every
25 building, room, enclosure, or premises occupied or used for the cultivation, production,
26 preparation, manufacture for sale, storage, and sale of medical cannabis, and to
27 inspect the premises and all equipment, apparatuses, fixtures, furniture, and
28 machinery used for the preparation thereof.

29 **SEC. 23. *Testing of Medical Cannabis.*** – The PMCA shall test all medical
30 cannabis products prior to their distribution, dispensation, and sale to determine their
31 potency, consistency, safe and effective use. It shall ensure that all medical cannabis
32 products are medical grade and safe for use.

33 It shall ensure that all medical cannabis products are individually wrapped at
34 the original point of preparation and conform to existing packaging and labeling
35 requirements of the PMCA and FDA.

1 **SEC. 24. Exemption from Civil and Criminal Liability.** – Subject to Section
2 25 of this Act, the following shall be exempt from civil and criminal liability:

- 3 a. The certifying physician, as defined in Section 9 of this Act, for issuing
4 written prescriptions stating that in the physician's professional opinion,
5 a patient is qualified to receive therapeutic or palliative benefit from the
6 medical use of cannabis to treat or alleviate the patient's debilitating
7 medical condition or symptoms;
- 8 b. A qualified patient for using medical cannabis in the prescribed dosage
9 and form for treatment of his debilitating medical condition as
10 determined by a certifying physician;
- 11 c. An authorized representative for assisting a registered qualified patient
12 for possessing not more than the exact prescribed dosage of cannabis
13 needed by the qualifying patient;
- 14 d. The licensed medical cannabis industry players and their personnel
15 authorized to dispense, cultivate, manufacture, or produce medical
16 cannabis as provided under this Act; and
- 17 e. Personnel of national government agencies tasked with testing medical
18 cannabis and cannabis products, and other similar undertakings which
19 would require handling, transporting or otherwise possessing cannabis
20 and cannabis products: *Provided*, That the said personnel of national
21 government agencies are authorized by the PMCA to perform such
22 undertakings: *Provided further*, That the said personnel are performing
23 such undertakings while on duty inside an authorized or licensed
24 cultivation, production, testing and dispensing facility.

25 **SEC. 25. Prohibited Acts.** – It shall be prohibited for:

- 26 a. A qualified patient to:
- 27 i. Use cannabis for purposes other than for treatment of a
28 debilitating medical condition and outside of the designated
29 treatment facilities;
- 30 ii. Use of cannabis with other illegal intoxicating or dangerous
31 substances; and
- 32 iii. Sell or give away medical cannabis.
- 33 b. Any physician to:
- 34 i. Prescribe medical cannabis without an S2 license;
- 35 ii. Prescribe medical cannabis to any person who is not a qualified
36 patient under this Act;
- 37 iii. Prescribe the use of medical cannabis for purposes other than for
38 treatment of a debilitating medical condition;

- 1 iv. Prescribe medical cannabis in quantity more than the needed
2 dosage;
3 v. Fail or refuse to maintain the record of all his or her patients and
4 prescriptions issued referred to in Section 9 of this Act; and
5 vi. Issue a written prescription for his or her own use, or the use of
6 his or her immediate family or relatives within the second civil
7 degree of consanguinity or affinity.
- 8 c. A Medical Cannabis Industry Player to:
- 9 i. Operate as a medical cannabis industry player without a license;
10 ii. Acquire, possess, deliver, transfer, transport, supply, or dispense
11 medical cannabis to any person except to registered qualified
12 patients or through their authorized representatives;
13 iii. Cultivate, manufacture, and store cannabis/medical cannabis in
14 violation of any of the provisions of this Act;
15 iv. Acquire usable cannabis or mature cannabis plants from illegal
16 sources;
17 v. Refer patients to an unqualified physician;
18 vi. Dispense without presentation of the certifying physician's written
19 prescription and valid registry ID card of the qualified patient or
20 its authorized representative;
21 vii. Dispense more than the required dosage for a patient; and
22 viii. Fail to scan the QR Code of any qualified patient and update the
23 Prescription Monitoring System prior to dispensing cannabis.
- 24 d. Any person or entity to:
- 25 i. Advertise the sale of medical cannabis in any manner, including
26 printed materials, on radio or television, social media, internet or
27 by paid-in-person solicitation of customers, and electronic games:
28 *Provided*, That this shall not be construed to prohibit medical
29 cannabis industry players from posting appropriate signages in
30 their place of business or operation, and from being included in
31 business directories, or sponsoring or organizing health, charity
32 or advocacy events, subject to the guidelines to be issued by the
33 PMCA;
34 ii. Violate the confidentiality of information under R.A. 10173,
35 otherwise known as the "*Data Privacy Act of 2012*";
36 iii. Purchase of medical cannabis when not authorized to do so;
37 iv. Falsifies an identification card issued by the DOH or an S2 license
38 or possesses a falsified identification card and either attempts to
39 use the card to obtain medical cannabis or obtains medical
40 cannabis. Any person using or possessing a falsified identification
41 card shall be presumed the author thereof; and

- 1 v. Discriminates any qualified patient from any services in public or
2 private establishment; employment in any public or private
3 institution; or admission to any academic institution: *Provided,*
4 That the qualified patient shall not partake in medical cannabis
5 within the premises of the place of employment or the academic
6 institution.

7 **SEC. 26. Penalties.** – Violation of any provisions of this Act shall be subject to
8 the penalties provided for under Republic Act No. 9165, as amended, or the
9 “Comprehensive Dangerous Drugs Act of 2002”.

10 **SEC. 27. Research and Development.** – The PMCA shall, within one hundred
11 twenty (120) days from the approval of this Act, use existing research made by
12 reputable international organizations, as well as research made or published by its
13 counterpart in countries wherein medical cannabis is administered.

14 **SEC. 28. Medical Cannabis Research and Development Fund.** – A portion
15 of the proceeds from licensing and registration of medical cannabis industry players
16 shall be earmarked for the medical cannabis industry research, protection and
17 development.

18 **SEC. 29. Training of Medical Cannabis Physicians, Pharmacists, and**
19 **Other Allied Medical and Health Care Professionals.** – The PMCA shall develop
20 an appropriate training program for physicians, pharmacists, and other allied medical
21 and health care professionals on the following topics: the pharmacology of cannabis;
22 contraindications; side effects; adverse reactions; overdose prevention; drug
23 interactions; dosing; routes of administration; risks and benefits; warnings and
24 precautions; abuse and dependence, and other related topics. Completion of the
25 program shall be a precondition for the physician, pharmacists, and other allied
26 medical and health care professionals, as may be licensed, to prescribe, dispense and
27 administer medical cannabis to qualified patients.

28 The PMCA shall coordinate with the Commission on Higher Education to
29 integrate the aforementioned topics on medical cannabis into the medical curriculum
30 of all medical schools, and academic curriculum for agriculture and applied science
31 and technology in all colleges and universities.

32 The PMCA shall likewise coordinate with the PRC for the development and
33 implementation of a Continuing Professional Development program on medical
34 cannabis for certified physicians.

35 **SEC. 30. Annual Reports.** – The PMCA shall submit an annual report to the
36 DOH and to both Houses of Congress, which shall include the following information:

- 1 a. Number of applications and renewals filed for registry identification cards;
- 2 b. Number of registered qualified patients at the time of report;
- 3 c. Nature of debilitating medical conditions of the qualified patients;
- 4 d. Number of physicians authorized to issue prescriptions;
- 5 e. Number of registry identification cards revoked for misconduct;
- 6 f. Number of medical cannabis industry players;
- 7 g. Assessment of the use of medical cannabis, research, and treatment of
- 8 patients with a debilitating medical condition; and
- 9 h. Other pertinent information.

10 **SEC. 31. *Joint Congressional Oversight Committee.*** – There is hereby
11 created a Joint Congressional Oversight Committee to conduct a regular review of the
12 implementation of this Act.

13 The Joint Congressional Oversight Committee shall be composed of five (5)
14 Members from the Senate and five (5) Members from the House of Representatives
15 to be appointed by the Senate President and the Speaker of the House of
16 Representatives, respectively. The Joint Congressional Oversight Committee shall be
17 jointly chaired by the Chairpersons of the Senate Committee on Health and
18 Demography and the House of Representatives Committee on Health.

19 **SEC. 32. *Implementing Rules and Regulations.*** – Within ninety (90) days
20 from the effectivity of this Act, the PMCA, in consultation with the appropriate
21 government agencies, shall promulgate rules and regulations necessary for the
22 effective implementation of this Act.

23 **SEC. 33. *Appropriations.*** – The amount necessary to carry out the
24 implementation of this Act shall be charged against the current year's appropriations
25 of the DOH. Thereafter, such sums as may be necessary for the continued
26 implementation of this Act shall be included in the annual General Appropriations Act.

27 **SEC. 34. *Separability Clause.*** – If any provision or part of this Act is declared
28 invalid or unconstitutional, the remaining parts or provisions not affected shall remain
29 in full force and effect.

30 **SEC. 35. *Repealing Clause.*** – For purposes of this Act, pertinent provisions
31 of Republic Act No. 9165, as amended, otherwise known as the "Comprehensive
32 Dangerous Drugs Act of 2002," as amended, and Republic Act No. 9711 or the "Food
33 and Drug Administration Act of 2019", and all other laws, decrees, orders, rules and
34 regulations, or parts thereof, inconsistent with any provision of this Act, are hereby
35 repealed or modified accordingly.

1 **SEC. 36. Effectivity.** – This Act shall take effect after fifteen (15) days from
2 its publication in the Official Gazette or in a newspaper of general circulation.

Approved,